As weight loss medications containing active ingredients like semaglutide continue to define a new chapter in metabolic ...
Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors. Its dose–response relationships with respect to side effects ...
A triple receptor agonist provided weight loss for adults with obesity, with or without type 2 diabetes, to an extent not ...
Retatrutide demonstrated substantial dose-dependent improvements in waist circumference and crucial cardiovascular risk factors, including non-HDL-C, triglycerides, systolic blood pressure, and ...
iPercent change in the WOMAC pain subscale score and percent change in the WOMAC physical function subscale score were not pre-specified and were estimated from a post-hoc analysis.iiNot controlled ...
The world of weight management is evolving faster than ever, and a new drug discovery is setting a historic milestone for ...
Retatrutide successfully reduces body weight among adults who don’t have diabetes but have obesity or overweight and at least one weight-related comorbidity, manufacturer Eli Lily and Company ...
Retatrutide met primary and key secondary endpoints in a 2339-participant, randomized, double-blind, placebo-controlled phase 3 trial, demonstrating clinically meaningful weight reduction across 4, 9, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results